person

Mihaela C.

Country
Romania
Department
Dispensar TBC

Research Overview

Data & Insights

medical_services
Primary Speciality
Main therapeutic area

handshake
Return Partnerships
Recurring site collaborations
0
Sites with multiple studies

Has run more than one trial at 0 of 69 partner sites.

Specializations

Chronic Obstructive Pulmonary Disease

The investigator concentrates on therapeutic strategies for Chronic Obstructive Pulmonary Disease and its exacerbation profile.

  • Exacerbation reduction
  • Bronchodilator optimization
  • Triple‑therapy add‑on evaluation
  • Inhaler propellant comparison
  • Long‑acting anti‑inflammatory agents

Research emphasizes real‑world outcomes and lung‑function preservation.

Asthma

Focused on advanced care for patients with asthma, especially severe and uncontrolled forms.

  • Severe uncontrolled asthma management
  • ICS/LABA/LAMA single‑inhaler efficacy
  • Biologic and novel small‑molecule interventions
  • Step‑wise guideline‑based treatment
  • Asthma control questionnaire outcomes

Efforts target reduction of exacerbation frequency and improvement of symptom control.

Interstitial Lung Disease & Pulmonary Fibrosis

Investigates disease‑modifying therapies for idiopathic pulmonary fibrosis and related interstitial lung conditions.

  • FVC change as primary endpoint
  • Intravenous antifibrotic agents
  • Safety profiling in progressive fibrosis
  • Combination with standard of care
  • Long‑term functional outcomes

Study designs aim to halt disease progression and preserve lung capacity.

Bronchiectasis

Addresses chronic infection and airway damage in patients with bronchiectasis.

  • Pulmonary exacerbation rate reduction
  • Novel anti‑inflammatory compounds
  • Safety versus placebo comparison
  • Quality‑of‑life assessments
  • Adjunctive antibiotic strategies

Therapeutic goals include decreasing exacerbations and improving airway health.

Pulmonary Hypertension Associated with Interstitial Lung Disease

Explores targeted interventions for pulmonary hypertension associated with interstitial lung disease.

  • Hemodynamic improvement metrics
  • Exercise capacity enhancement
  • Combination with antifibrotic therapy
  • Safety in dual‑disease populations
  • Long‑term survival outcomes

Research seeks to mitigate vascular complications while preserving lung function.

Related Investigators

Researchers in similar fields or departments

Want to know more about this investigator?

We can share extended profile information and contact details.

Is something out of date?

Tell us what needs correcting and we'll update this profile.